Studies side effects after cancer immunotherapy
Part of Cancer clinical trials.
This study collects information and biological samples from people who have had significant side effects after immunotherapy for cancer. It aims to understand why these side effects happen and how to improve care for patients in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received cancer treatment that includes an immunotherapy (immuno-oncology therapy).
- After starting that immunotherapy, you had immune-related side effects such as serious (Grade 3–4) side effects, or moderate (Grade 2) skin or joint/muscle-related side effects.
- You developed a rare infection (like fungal or mycobacterial) after starting immunotherapy (but not COVID-19).
- If you had “hyperprogression” (the cancer seemed to worsen unusually fast), you must be able to submit required images for review.
- You have not already been enrolled/registered in this same study before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to improve how doctors spot and track side effects from immunotherapy. If you are on or have had immunotherapy, your experience can help build a better system for monitoring these treatments.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
This study looks at how immune-related side effects happen in people treated with certain cancer immunotherapies. It also includes some healthy volunteers and people who already have similar autoimmune conditions, to better understand and compare these reactions.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
This study looks at side effects from immunotherapy in people with solid or blood cancers. It may help doctors better manage these side effects in the future.
This study looks at how side effects happen in people receiving immune checkpoint inhibitor immunotherapy for solid cancers. It uses multiple types of tests to better understand these toxicities and may help improve safety and care in the future.
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.